August 7, 2020
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies. The Food and Drug Administration has granted accelerated approval to a drug for multiple myeloma that is the first of...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand